Skip to main content

Table 1 Baseline characteristics of enrolled patients

From: High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study

Total n = 117 Number or median value
Age, median (range) 44 (19–70)
Gender, male 70 (59.8%)
Laboratory findings at diagnosis
 Leukocyte count (×109/L) 2.68 (0.4–112.0)
  Leukocytes count at peak (×109/L) 16.6 (0.4–112.0)
 Hemoglobin (g/dL) 8.9 (4.0–15.0)
 Platelet (×109/L) 33.0 (5.0–163.0)
 Lactate dehydrogenase (LDH, U/L) 692 (250–4070)
 Prothrombin time (PT, %) 63.0 (35.0–101.0%)
 Partial thromboplastin time (aPTT, s) 28.0 (20–45)
 Fibrinogen (mg/dL) 134.0 (31.0–500.0)
 Antithrombin III (%) 94.0 (49.0–150.0)
 D-dimer (mg/L) 17.0 (1.0–36.0)
Sanz criteria
 High 64 (54.7%)
 Intermediate 19 (16.2%)
 Low 34 (29.1%)
Karyotype
 Normal karyotype 5 (4.3%)
 t(15;17) alone 79 (67.5%)
 t(15;17) with 1 additional karyotype 20 (17.1%)
 t(15;17) with ≥2 additional karyotype 13 (11.1%)
PML-RARa subtype
 BCR1 85 (72.6%)
 BCR3 32 (27.4%)
FLT3 mutation
 No FLT3 mutation 86 (73.5%)
FLT3-ITD 25 (21.4%)
FLT3-TKD 6 (5.1%)
WT1 (copies/104 ABL), median (range)
 At diagnosis (n = 117) 18330 (20.0–236160.0)
 Post-induction (n = 117) 63.9 (4.9–2360.0)
 Post 1st consolidation (n = 117) 66.2 (1.1–2320.0)
 Post 2nd consolidation (n = 117) 80.1 (1.3–2110.0)
 Post 3rd consolidation (n = 117) 71.9 (10.8–808.0)
aPost-maintenance 3 months (n = 117) 70.0 (6.0–5520.0)
aPost-maintenance 1 year (n = 87) 57.5 (10.0–1630.0)
aPost-maintenance 2 year (n = 62) 54.4 (10.0–500.0)
 At relapse (n = 16) 239.5 (77.1–34910.0)
Leukapheresis at initial treatment 20 (17.1%)
Differentiation syndrome 21 (17.9%)
Hematological complete response
 After induction 115 (98.3%)
 After 2nd induction 2 (1.7%)
Complete molecular response (CMR)
 After induction 68 (58.1%)
 After 2nd induction 2 (1.7%)
 After 1st consolidation 42 (35.9%)
 After 2nd consolidation 5 (4.3%)
  1. Abbreviation: BCR breakpoint cluster region, FLT3 Fms-related tyrosine kinase 3, ITD internal tandem duplication, TKD tyrosine kinase domain, ABL Abelson murine leukemia viral oncogene, WT1, Wilms tumor 1, ATRA all-trans retinoic acid, AML acute myeloid leukemia
  2. aPost-maintenance indicates the time from starting maintenance therapy